Skip to main content
. 2020 Oct 9;3(6):1265–1277. doi: 10.1021/acsptsci.0c00130

Figure 2.

Figure 2

Enzymatic assay of SARS-CoV-2 Mpro, PLpro, EV-A71 and EV-D68 2Apro, and 3Cpro against inhibitors investigated in this study. (A) SARS-CoV-2 Mpro; (B) SARS-CoV-2 PLPro; (C) EV-A71 2Apro; (D) EV-A71 3Cpro; (E) EV-D68 2Apro; and (F) EV-D68 3Cpro. Protease was preincubated in their corresponding reaction buffer as described in the “Materials and Method” section with various concentrations of protease inhibitors in the presence of 4 mM DTT or in the absence of DTT at 30 °C for 30 min. The enzymatic reaction was initiated by adding the corresponding FRET substrate. The efficacy of these protease inhibitors in the presence of 4 mM DTT or in the absence of DTT was evaluated with a four-parameter dose–response curve function in prism 8 as described in the “Materials and Method” section.